Research programme: anthrax vaccine - Baxter Healthcare
Latest Information Update: 01 Apr 2011
At a glance
- Originator Baxter International
- Developer Roche
- Class Anthrax vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Anthrax
Most Recent Events
- 26 Jun 2007 BioVeris Corporation has been acquired and merged into Roche